



September 29, 2022

✓ **BSE Limited**

Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001

The National Stock Exchange of India Ltd.,

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051

Dear Sir/Madam,

**Re: Disclosure pursuant to Regulation 30 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

Subject: Communication from U.S. FDA regarding the Company's Tarapur, Maharashtra (India) facility.

We wish to inform you that the Company has received a warning letter from the U.S. FDA for the Company's Tarapur, Maharashtra (India) facility. The U.S. FDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022.

The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

We are committed to addressing the concerns raised by the U.S. FDA and will work with the U.S. FDA to resolve these issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all our facilities.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**